KORU Medical Systems to Release Q2 2025 Financial Results on August 6, 2025.
PorAinvest
domingo, 20 de julio de 2025, 12:56 am ET1 min de lectura
KRMD--
Investors and analysts can join the conference call by dialing (877)-407-0784 for participants in the U.S. or Canada, and (201)-689-8560 for international callers. A live and archived webcast of the event will be available via the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com. The archived webcast will be available for six months.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions. The company’s flagship product, the Freedom Syringe Infusion System (Freedom System), includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by patients and delivery in ambulatory infusion centers by healthcare professionals. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and can customize the Freedom System for clinical and commercial use across multiple drug categories.
References:
[1] https://www.stocktitan.net/news/KRMD/koru-medical-systems-to-report-second-quarter-2025-financial-results-rx4j6qhlwwkn.html
[2] https://finance.yahoo.com/news/koru-medical-systems-report-second-200500243.html
[3] https://www.barchart.com/story/news/33447505/koru-medical-systems-to-report-second-quarter-2025-financial-results-on-august-6-2025
KORU Medical Systems plans to release Q2 2025 financial results on August 6, 2025. The company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the results and provide a corporate update. Investors can dial (877)-407-0784 or (201)-689-8560 to join the conference call, while a live and archived webcast will be available on the company's website.
Mahwah, N.J., July 2, 2025 – KORU Medical Systems, Inc. (NASDAQ: KRMD), a leading medical technology company, has announced that it will release its second quarter 2025 financial results on Wednesday, August 6, 2025. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update.Investors and analysts can join the conference call by dialing (877)-407-0784 for participants in the U.S. or Canada, and (201)-689-8560 for international callers. A live and archived webcast of the event will be available via the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com. The archived webcast will be available for six months.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions. The company’s flagship product, the Freedom Syringe Infusion System (Freedom System), includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by patients and delivery in ambulatory infusion centers by healthcare professionals. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and can customize the Freedom System for clinical and commercial use across multiple drug categories.
References:
[1] https://www.stocktitan.net/news/KRMD/koru-medical-systems-to-report-second-quarter-2025-financial-results-rx4j6qhlwwkn.html
[2] https://finance.yahoo.com/news/koru-medical-systems-report-second-200500243.html
[3] https://www.barchart.com/story/news/33447505/koru-medical-systems-to-report-second-quarter-2025-financial-results-on-august-6-2025

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios